Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
Clinical trial NCT00483262 · COMPLETED
Trial details
- NCT number
- NCT00483262
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-05-01
- Primary completion
- 2011-01-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.